Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
OBJECTIVE
To evaluate the possible pharmacokinetic interaction between nefazodone and lithium.


METHODS
Twelve healthy volunteers received nefazodone 200 mg b.i.d. for 5 days. A 4-day washout phase followed from day 6 to day 9. From day 10 to day 20, escalating doses of lithium 250 mg b.i.d. to 500 mg b.i.d. were given; the daily dose of 1000 mg was obtained on day 13. From day 16 to day 20, nefazodone 200 mg b.i.d. was added to the lithium dosing regimen. Venous blood sampling was performed on days 5, 15 and 20 for 0- to 48-h-pharmacokinetic analysis. Nefazodone and its metabolites, hydroxynefazodone, mCPP and triazoledione were assayed by high-performance liquid chromatography (HPLC). Lithium was assayed by flame photometry.


RESULTS
Co-administration of nefazodone did not modify pharmacokinetic parameters of lithium at steady-state. Comparison of the area under the plasma or serum concentration-versus-time curve calculated from 0-12 h (AUC0-12) of nefazodone and hydroxynefazodone revealed no significant differences when nefazodone was administered alone or with lithium. The mean maximum peak plasma concentration Cmax and AUC0-12 of meta-chlorophenyl-piperazine (mCPP) were significantly reduced by 27% (P < 0.001) and 16% (P < 0.001) with the co-administration. The mean Cmax and AUC0-12 of triazoledione were reduced by 23% (P < 0.005) and 16% (P < 0.01) by the co-administration.


CONCLUSIONS
Since there were no clinically significant changes in the pharmacokinetics of the parent compounds or metabolites, and the combination was well tolerated, no dosage adjustments of nefazodone or lithium are necessary when they are co-administered.
Laroudie
C
C
Département de Recherche Clinique SNC, Bristol-Myers Squibb Pharmaceutical Research Institute, Paris La Défense, France.
Salazar
D E
DE
Cosson
J P
JP
Cheuvart
B
B
Istin
B
B
Girault
J
J
Ingrand
I
I
Decourt
J P
JP
D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D008297:Male; D010783:Photometry; D010879:Piperazines; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis / Q000378:metabolism / Q000493:pharmacokinetics*
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C092333:hydroxynefazodone; C051752:nefazodone; D008094:Lithium